갑상선 질환 치료 시장(2026-2030년)

The global thyroid gland disorder treatment market is forecasted to grow by USD 940.2 mn during 2025-2030, accelerating at a CAGR of 5.1% during the forecast period. The report on the global thyroid gland disorder treatment market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by surging prevalence of autoimmune and chronic thyroid disorders, advancements in diagnostic infrastructure and public screening initiatives, technological progress in drug formulations and digital healthcare integration.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market size data, segment with regional analysis and vendor landscape in addition to an analysis of the key companies. Reports have historic and forecast data.

Technavio's global thyroid gland disorder treatment market is segmented as below:

By Type

• Hypothyroidism
• Hyperthyroidism

By Distribution Channel

• Offline
• Online

By Route Of Administration

• Oral
• Intravenous

By Drug Class

• Hormone replacement therapies
• Anti-thyroid drugs
• Others

Geography

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • The Netherlands
• Asia
• Rest of World (ROW)
• Rest of World (ROW)

This study identifies the proliferation of digital therapeutics and tele-endocrinology infrastructure as one of the prime reasons driving the global thyroid gland disorder treatment market growth during the next few years. Also, shift toward precision oncology and targeted multikinase inhibitor formulations and rising consumer integration of specialized nutraceuticals and preventative thyroid supplements will lead to sizable demand in the market.

The report on the global thyroid gland disorder treatment market covers the following areas:

• Global thyroid gland disorder treatment market sizing
• Global thyroid gland disorder treatment market forecast
• Global thyroid gland disorder treatment market industry analysis

The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading global thyroid gland disorder treatment market vendors that include Abbisko Therapeutics Co. Ltd., AbbVie Inc., Acella Pharmaceuticals LLC, Amneal Pharmaceuticals Inc., ANI Pharmaceuticals Inc., Aspen Pharmacare Ltd., Bayer AG, Egetis Therapeutics AB, Eli Lilly and Co., Fresenius Kabi AG, Hikma Pharmaceuticals Plc, IBSA Institut Biochimique SA, Lupin Ltd., Merck KGaA, Novartis AG, Pfizer Inc., Piramal Pharma Ltd., RLC Labs Inc., Sanofi SA, Takeda Pharmaceutical Ltd., Viatris Inc.. Also, the global thyroid gland disorder treatment market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive primary and secondary research. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.

Table of Contents

1 Executive Summary

• 1.1 Market overview
  • Executive Summary - Chart on Market Overview
  • Executive Summary - Data Table on Market Overview
  • Executive Summary - Chart on Global Market Characteristics
  • Executive Summary - Chart on Market by Geography
  • Executive Summary - Chart on Market Segmentation by Type
  • Executive Summary - Chart on Market Segmentation by Distribution Channel
  • Executive Summary - Chart on Market Segmentation by Route of Administration
  • Executive Summary - Chart on Market Segmentation by Drug Class
  • Executive Summary - Chart on Incremental Growth
  • Executive Summary - Data Table on Incremental Growth
  • Executive Summary - Chart on Company Market Positioning

2 Technavio Analysis

• 2.1 Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
  • Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
• 2.2 Criticality of inputs and Factors of differentiation
• 2.3 Factors of disruption
• 2.4 Impact of drivers and challenges

3 Market Landscape

• 3.1 Market ecosystem
• 3.2 Market characteristics
• 3.3 Value chain analysis

4 Market Sizing

• 4.1 Market definition
• 4.2 Market segment analysis
  • Market segments
• 4.3 Market size 2025
• 4.4 Market outlook: Forecast for 2025-2030

5 Historic Market Size

• 5.1 Global Thyroid Gland Disorder Treatment Market 2020 - 2024
  • Historic Market Size - Data Table on Global Thyroid Gland Disorder Treatment Market 2020 - 2024 ($ million)
• 5.2 Type segment analysis 2020 - 2024
  • Historic Market Size - Type Segment 2020 - 2024 ($ million)
• 5.3 Distribution Channel segment analysis 2020 - 2024
  • Historic Market Size - Distribution Channel Segment 2020 - 2024 ($ million)
• 5.4 Route of Administration segment analysis 2020 - 2024
  • Historic Market Size - Route of Administration Segment 2020 - 2024 ($ million)
• 5.5 Drug Class segment analysis 2020 - 2024
  • Historic Market Size - Drug Class Segment 2020 - 2024 ($ million)
• 5.6 Geography segment analysis 2020 - 2024
  • Historic Market Size - Geography Segment 2020 - 2024 ($ million)
• 5.7 Country segment analysis 2020 - 2024
  • Historic Market Size - Country Segment 2020 - 2024 ($ million)

6 Qualitative Analysis

• 6.1 Impact of AI on global thyroid gland disorder treatment market
• 6.2 Impact of geopolitical conflicts on global thyroid gland disorder treatment market

7 Five Forces Analysis

• 7.1 Five forces summary
  • Five forces analysis - Comparison between 2025 and 2030
• 7.2 Bargaining power of buyers
  • Bargaining power of buyers - Impact of key factors 2025 and 2030
• 7.3 Bargaining power of suppliers
  • Bargaining power of suppliers - Impact of key factors in 2025 and 2030
• 7.4 Threat of new entrants
  • Threat of new entrants - Impact of key factors in 2025 and 2030
• 7.5 Threat of substitutes
  • Threat of substitutes - Impact of key factors in 2025 and 2030
• 7.6 Threat of rivalry
  • Threat of rivalry - Impact of key factors in 2025 and 2030
• 7.7 Market condition

8 Market Segmentation by Type

• 8.1 Market segments
• 8.2 Comparison by Type
• 8.3 Hypothyroidism - Market size and forecast 2025-2030
• 8.4 Hyperthyroidism - Market size and forecast 2025-2030
• 8.5 Market opportunity by Type
  • Market opportunity by Type ($ million)

9 Market Segmentation by Distribution Channel

• 9.1 Market segments
• 9.2 Comparison by Distribution Channel
• 9.3 Offline - Market size and forecast 2025-2030
• 9.4 Online - Market size and forecast 2025-2030
• 9.5 Market opportunity by Distribution Channel
  • Market opportunity by Distribution Channel ($ million)

10 Market Segmentation by Route of Administration

• 10.1 Market segments
• 10.2 Comparison by Route of Administration
• 10.3 Oral - Market size and forecast 2025-2030
• 10.4 Intravenous - Market size and forecast 2025-2030
• 10.5 Market opportunity by Route of Administration
  • Market opportunity by Route of Administration ($ million)

11 Market Segmentation by Drug Class

• 11.1 Market segments
• 11.2 Comparison by Drug Class
• 11.3 Hormone replacement therapies - Market size and forecast 2025-2030
• 11.4 Anti-thyroid drugs - Market size and forecast 2025-2030
• 11.5 Others - Market size and forecast 2025-2030
• 11.6 Market opportunity by Drug Class
  • Market opportunity by Drug Class ($ million)

12 Customer Landscape

• 12.1 Customer landscape overview
  • Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

13 Geographic Landscape

• 13.1 Geographic segmentation
• 13.2 Geographic comparison
• 13.3 North America - Market size and forecast 2025-2030
  • 13.3.1 US - Market size and forecast 2025-2030
  • 13.3.2 Canada - Market size and forecast 2025-2030
  • 13.3.3 Mexico - Market size and forecast 2025-2030
• 13.4 Europe - Market size and forecast 2025-2030
  • 13.4.1 Germany - Market size and forecast 2025-2030
  • 13.4.2 UK - Market size and forecast 2025-2030
  • 13.4.3 France - Market size and forecast 2025-2030
  • 13.4.4 Italy - Market size and forecast 2025-2030
  • 13.4.5 Spain - Market size and forecast 2025-2030
  • 13.4.6 The Netherlands - Market size and forecast 2025-2030
• 13.5 Asia - Market size and forecast 2025-2030
  • 13.5.1 China - Market size and forecast 2025-2030
  • 13.5.2 Japan - Market size and forecast 2025-2030
  • 13.5.3 India - Market size and forecast 2025-2030
  • 13.5.4 South Korea - Market size and forecast 2025-2030
  • 13.5.5 Indonesia - Market size and forecast 2025-2030
  • 13.5.6 Thailand - Market size and forecast 2025-2030
• 13.6 Rest of World (ROW) - Market size and forecast 2025-2030
  • 13.6.1 Brazil - Market size and forecast 2025-2030
  • 13.6.2 Australia - Market size and forecast 2025-2030
  • 13.6.3 Saudi Arabia - Market size and forecast 2025-2030
  • 13.6.4 South Africa - Market size and forecast 2025-2030
  • 13.6.5 Argentina - Market size and forecast 2025-2030
  • 13.6.6 UAE - Market size and forecast 2025-2030
  • 13.6.7 Chile - Market size and forecast 2025-2030
  • 13.6.8 Israel - Market size and forecast 2025-2030
• 13.7 Market opportunity by geography
  • Market opportunity by geography ($ million)
  • Data Tables on Market opportunity by geography ($ million)

14 Drivers, Challenges, and Opportunity

• 14.1 Market drivers
  • Surging prevalence of autoimmune and chronic thyroid disorders
  • Advancements in diagnostic infrastructure and public screening initiatives
  • Technological progress in drug formulations and digital healthcare integration
• 14.2 Market challenges
  • Stringent bioequivalence regulations and narrow therapeutic index limitations
  • Supply chain vulnerabilities and frequent product recalls
  • Diagnostic backlogs and low public awareness in emerging economies
• 14.3 Impact of drivers and challenges
  • Impact of drivers and challenges in 2025 and 2030
• 14.4 Market opportunities
  • Proliferation of digital therapeutics and tele-endocrinology infrastructure
  • Shift toward precision oncology and targeted multikinase inhibitor formulations
  • Rising consumer integration of specialized nutraceuticals and preventative thyroid supplements

15 Competitive Landscape

• 15.1 Overview
• 15.2 Competitive Landscape
  • Overview on criticality of inputs and factors of differentiation
• 15.3 Landscape disruption
  • Overview on factors of disruption
• 15.4 Industry risks
  • Impact of key risks on business

16 Competitive Analysis

• 16.1 Companies profiled
  • Companies covered
• 16.2 Company ranking index
  • Company ranking index
• 16.3 Market positioning of companies
  • Matrix on companies position and classification
• 16.4 AbbVie Inc.
  • AbbVie Inc. - Overview
  • AbbVie Inc. - Business segments
  • AbbVie Inc. - Key news
  • AbbVie Inc. - Key offerings
  • AbbVie Inc. - Segment focus
  • SWOT
• 16.5 Amneal Pharmaceuticals Inc.
  • Amneal Pharmaceuticals Inc. - Overview
  • Amneal Pharmaceuticals Inc. - Business segments
  • Amneal Pharmaceuticals Inc. - Key offerings
  • Amneal Pharmaceuticals Inc. - Segment focus
  • SWOT
• 16.6 Bayer AG
  • Bayer AG - Overview
  • Bayer AG - Business segments
  • Bayer AG - Key offerings
  • Bayer AG - Segment focus
  • SWOT
• 16.7 Eli Lilly and Co.
  • Eli Lilly and Co. - Overview
  • Eli Lilly and Co. - Product / Service
  • Eli Lilly and Co. - Key news
  • Eli Lilly and Co. - Key offerings
  • SWOT
• 16.8 Fresenius Kabi AG
  • Fresenius Kabi AG - Overview
  • Fresenius Kabi AG - Product / Service
  • Fresenius Kabi AG - Key offerings
  • SWOT
• 16.9 Hikma Pharmaceuticals Plc
  • Hikma Pharmaceuticals Plc - Overview
  • Hikma Pharmaceuticals Plc - Business segments
  • Hikma Pharmaceuticals Plc - Key news
  • Hikma Pharmaceuticals Plc - Key offerings
  • Hikma Pharmaceuticals Plc - Segment focus
  • SWOT
• 16.10 IBSA Institut Biochimique SA
  • IBSA Institut Biochimique SA - Overview
  • IBSA Institut Biochimique SA - Product / Service
  • IBSA Institut Biochimique SA - Key offerings
  • SWOT
• 16.11 Lupin Ltd.
  • Lupin Ltd. - Overview
  • Lupin Ltd. - Business segments
  • Lupin Ltd. - Key news
  • Lupin Ltd. - Key offerings
  • Lupin Ltd. - Segment focus
  • SWOT
• 16.12 Merck KGaA
  • Merck KGaA - Overview
  • Merck KGaA - Business segments
  • Merck KGaA - Key news
  • Merck KGaA - Key offerings
  • Merck KGaA - Segment focus
  • SWOT
• 16.13 Novartis AG
  • Novartis AG - Overview
  • Novartis AG - Business segments
  • Novartis AG - Key news
  • Novartis AG - Key offerings
  • Novartis AG - Segment focus
  • SWOT
• 16.14 Pfizer Inc.
  • Pfizer Inc. - Overview
  • Pfizer Inc. - Business segments
  • Pfizer Inc. - Key news
  • Pfizer Inc. - Key offerings
  • Pfizer Inc. - Segment focus
  • SWOT
• 16.15 Piramal Pharma Ltd.
  • Piramal Pharma Ltd. - Overview
  • Piramal Pharma Ltd. - Business segments
  • Piramal Pharma Ltd. - Key offerings
  • Piramal Pharma Ltd. - Segment focus
  • SWOT
• 16.16 Sanofi SA
  • Sanofi SA - Overview
  • Sanofi SA - Business segments
  • Sanofi SA - Key news
  • Sanofi SA - Key offerings
  • Sanofi SA - Segment focus
  • SWOT
• 16.17 Takeda Pharmaceutical Ltd.
  • Takeda Pharmaceutical Ltd. - Overview
  • Takeda Pharmaceutical Ltd. - Business segments
  • Takeda Pharmaceutical Ltd. - Key news
  • Takeda Pharmaceutical Ltd. - Key offerings
  • Takeda Pharmaceutical Ltd. - Segment focus
  • SWOT
• 16.18 Viatris Inc.
  • Viatris Inc. - Overview
  • Viatris Inc. - Business segments
  • Viatris Inc. - Key news
  • Viatris Inc. - Key offerings
  • Viatris Inc. - Segment focus
  • SWOT

17 Appendix

• 17.1 Scope of the report
  • Market definition
  • Objectives
  • Notes and caveats
• 17.2 Inclusions and exclusions checklist
  • Inclusions checklist
  • Exclusions checklist
• 17.3 Currency conversion rates for US$
  • Currency conversion rates for US$
• 17.4 Research methodology
  • Research methodology
• 17.5 Data procurement
  • Information sources
• 17.6 Data validation
  • Data validation
• 17.7 Validation techniques employed for market sizing
  • Validation techniques employed for market sizing
• 17.8 Data synthesis
  • Data synthesis
• 17.9 360 degree market analysis
  • 360 degree market analysis
• 17.10 List of abbreviations
  • List of abbreviations